research use only

Teicoplanin Bacterial chemical

Cat.No.S1399

Teicoplanin (Teichomycin,Targocid,MDL-507) is a glycopeptide antibiotic, used to treat serious infections caused by Gram-positive bacteria.
Jump to

Quality Control

Batch: Purity: 99.34%
99.34

Solubility

In vitro
Batch:

Water : 100 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 1709.39 Formula

C77H77N9O31Cl2·R

Storage (From the date of receipt)
CAS No. 61036-62-2 Download SDF Storage of Stock Solutions

Synonyms Teichomycin,Targocid,MDL-507 SMILES CCCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)OC1C(C(C(C(O1)CO)O)O)NC(=O)C)Cl)CO)O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro

Teicoplanin is associated with small increases in the GI colonization by C. albicans. The inhibitory action of this compound on proteoglycan polymerization but not on nucleic acid and protein synthesis indicates that the effect in the wall is due to the accumulation at this level of proteoglycan soluble precursors continuously produced by the cell. It, at a concentration of 1 mg/mL, causes rapid lysis of exponential phase cells of Streptococcus faecalis. This compound inhibits peptidoglycan synthesis in intact cells and in cell-free systems. This chemical-induced lysis is dependent on the growth phase of B. pumilus at the time of addition of the antibiotic. It induces lysis after a longer lag phase with slowly growing Strep. jhecalis CCM 1875 and lysis is not very extensive.

In vivo

Teicoplanin therapy increases the survival rate whereas G-CSF therapy does not in comparison to other groups in neutropenic mice. This compound and G-CSF combination therapy improves survival rate when compared with groups II, III, IV.

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/1830328/
  • [5] https://pubmed.ncbi.nlm.nih.gov/12678538/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-02-10)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06818565 NOT_YET_RECRUITING
Acute-On-Chronic Liver Failure
Institute of Liver and Biliary Sciences, India
2025-02-10
NCT06803758 RECRUITING
Drug Allergy
University Hospital Southampton NHS Foundation Trust
2025-01-08
NCT06426836 RECRUITING
Pharmacokinetics; Amoxicillin-clavulanate; Piperacillin-tazobactam; Meropenem; Cefazolin; Teicoplanin; Vancomycin; Ciprofloxacin; Amikacin
University Hospital, Ghent
2016-08-19
NCT05914467 TERMINATED
Bacterial Infections
Radboud University Medical Center
2023-08-01 PHASE4
NCT02652169 RECRUITING
Chronic Skin Ulcer
Medical University of Vienna
2014-06
NCT04370145 COMPLETED
Cholangitis, Secondary Biliary; Treatment Compliance; Antibodies Drug Specific
Tongji Hospital
2021-05-01 PHASE4

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.